Health and Economic Burden of HPV-related Diseases in Singapore |
Low, Jeffrey Jen Hui
(Department of Obstetrics & Gynecology, National University Hospital System)
Ko, Yu (Department of Pharmacy, National University of Singapore) Ilancheran, Arunachalam (Department of Obstetrics & Gynecology, National University Hospital System) Zhang, Xu Hao (Medical Department, Merck Sharp & Dhome (I.A.) Corp. (Singapore Branch)) Singhal, Puneet K. (Global Outcomes Research and Reimbursement, Merck & Co., Inc.) Tay, Sun Kuie (Department of Obstetrics & Gynaecology, Singapore General Hospital) |
1 | Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189, 12-9. DOI |
2 | Wiley D, Masongsong E (2006). Human papillomavirus: the burden of infection. Obstet Gynecol Surv 61, S3-14. DOI |
3 | Wong WK (2008). Population Trends 2008 (Singapore Department of Statistics). |
4 | Insinga RP (2006). Annual productivity costs due to cervical cancer mortality in the United States. Womens Health Issues, 16, 236-42. DOI |
5 | Insinga RP, Dasbach EJ, Elbasha EH (2005). Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics, 23, 1107-22. DOI |
6 | Koutsky LA, Harper DM (2006). Chapter 13: Current findings from prophylactic HPV vaccine trials. Vaccine, 24, S3/114-21. |
7 | Ministry of Health, Singapore (2009). Communicable diseases surveillance in Singapore 2008. |
8 | Kulasingam SL, Hughes JP, Kiviat NB, et al (2002). Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA, 288, 1749-57. DOI |
9 | Lipsy RJ (2008). Assessing the short-term and long-term burden of illness in cervical cancer. Am J Manag Care, 14, S177-84. |
10 | Max W, Rice DP, Sung HY, et al (2003). The economic burden of gynecologic cancers in California, 1998. Gynecol Oncol, 88, 96-103. DOI |
11 | National Health Insurance Research Database (2009). Disease Burden of Genital Wart in Taiwan. |
12 | National Skin Center (2006). Sexually Transmitted Infections Notification Report. |
13 | Paavonen J, Naud P, Salmeron J, et al (2009). Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet, 374, 301-14. DOI |
14 | Parkin DM, Bray F (2006). Chapter 2: The burden of HPVrelated cancers. Vaccine, S3, 11-25. |
15 | Singapore Cancer Registry (2004). Trends in cancer incidence in Singapore 1968-2002 (Singapore,), pp. xi, 181 , 181 map 129 cm. + 181 CD-ROM (184 183/184 in.) |
16 | Ebrahim SH, McKenna MT, Marks JS (2005). Sexual behaviour: related adverse health burden in the United States. Sex Transm Infect, 81, 38-40. DOI |
17 | Annemans L, Remy V, Lamure E, et al (2008). Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium. J Med Econ, 11, 135-50. DOI |
18 | Chaturvedi AK (2010). Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health, 46, S20-6. |
19 | Dillner J, Kjaer SK, Wheeler CM, et al (2010). Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ, 341, c3493. DOI |